The combination of CBD and THCV (tetrahydrocannabivarin) looks to have significant therapeutic potential in the treatment of Type 2 diabetes. Research concerning THCV and Type 2 diabetes has been making scientific news for at least three years. THCV is what chemists call the propyl variant of THC. While THCV is psychoactive, it’s a shorter, more intense high than THC. THC is a few hours at the amusement park; THCV is an hour on the roller coaster.
Appetite suppression is another side effect of THCV. The science concerning THCV and weight loss is not well-developed. No one knows how long the effect lasts and how much weight loss can be expected. Even with that caveat, the possibilities are intriguing. The weight-loss industry is worth $60 billion a year, the same as the cannabis industry. What happens when those two industries intersect? Venture capital apoplexy. World domination.
It turns out that there aren’t any high THCV/CBD strains out there. Even THCV by itself is hard to find in any significant concentration. The strains Jack the Ripper and Durban Poison have approximately 2% THCV. Doug’s Varin has closer to 7% THCV, but it has a reputation as a scrawny plant. The strain Willie Nelson has some THCV, but none of the people in my circles know anything about it.
There is a micro-grow (10 plants) in Sonoma County with a strain code named Elizabeth Taylor with 6.7% THCV and 12% THC. It’s a robust plant with the highest terpene (essential oils that give cannabis strains their unique aromatics) profile measured around here.
The big-market potential from secondary cannabinoids, thin science and the lack of THCV/CBD rich genetics is (IMO) the perfect opportunity for any forward-thinking entrepreneur. Whether it’s THCV or something else (CBDV?), our cannabis future, both economic and cultural, will be shaped, not by what we know, but by what we will be able to learn.